Indegene

Indegene Forward P/E

The Forward P/E Ratio of Indegene (INDGN.NS) as of Oct 21, 2026 is 28.37. In the previous year, Forward P/E Ratio was 27.98 — a change of 1.40% (higher).

Forward P/E

28.37

YoY

1.40%

Last updated:

Forward P/E Ratio of Indegene is 2026 28.37 . Forward P/E Ratio of Indegene was 2025 27.98 . It decreases by 1.40% higher compared to the previous year.

The Indegene Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2020
203.89 INR
Jan 1, 2021
76.16 INR
Jan 1, 2022
69.06 INR
Jan 1, 2023
42.76 INR
Jan 1, 2024
33.80 INR
Jan 1, 2025
27.98 INR
Jan 1, 2026
28.37 INR
The Indegene Forward P/E history
YEARForward P/EYoY
28.37+1.40%
27.98-17.21%
33.80-20.97%
42.76-38.08%
69.06-9.32%
76.16-62.65%
203.89—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Indegene Stock analysis

What does Indegene do? Indegene Ltd generates revenue by providing digital-led commercialization services to life sciences companies, including biopharmaceutical, emerging biotech, and medical devices firms. The company assists these clients with drug development, clinical trials, regulatory submissions, pharmacovigilance, complaints management, and the sales and marketing of their products. This comprehensive support structure allows Indegene to serve as a key partner in the end-to-end commercialization process for its diverse client base within the life sciences sector. The company monetizes its offerings through specialized solution segments such as Omnichannel Activation, which helps life sciences companies leverage a digital first approach for optimizing the last-mile promotion of biopharmaceutical products and medical devices to healthcare professionals across multiple channels. Additionally, Enterprise Commercial Solutions primarily involves assisting life sciences companies with their digital marketing operations, further expanding the company's service portfolio and revenue streams. Revenue is also derived from Enterprise Medical Solutions, where Indegene establishes centers of excellence to consolidate large scale regulatory and medical operations for its clients. The company rounds out its business model by offering enterprise clinical solutions and consultancy services, ensuring a holistic service delivery model that addresses various operational needs of its customers in the life sciences industry. Indegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Indegene stock

Forward P/E Ratio of Indegene is 28.37 in 2026.

Forward P/E Ratio of Indegene changed from 27.98 to 28.37, representing a 1.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Indegene since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Indegene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Indegene

All Key Metrics — Indegene